Nusinersen demonstrates greater efficacy in infants with shorter disease duration: End of study results from the ENDEAR study in infants with spinal muscular atrophy (SMA)

被引：5

作者：

Servais, L. ^{[1
]}

Farrar, M. ^{[2
,3
]}

Finkel, R. ^{[4
]}

Kirschner, J. ^{[5
]}

Muntoni, F. ^{[6
]}

Sun, P. ^{[7
]}

Gheuens, S. ^{[7
]}

Schneider, E. ^{[8
]}

Farwell, W. ^{[7
]}

机构：

[1] Inst Myol, Paris, France

[2] Sydney Childrens Hosp Network, Sydney, NSW, Australia

[3] Univ New South Wales, Sydney, NSW, Australia

[4] Nemours Childrens Hosp, Orlando, FL USA

[5] Univ Freiburg, Med Ctr, Freiburg, Germany

[6] UCL, London, England

[7] Biogen, Cambridge, MA USA

[8] Ionis Pharmaceut Inc, Carlsbad, CA USA

来源：

关键词：

D O I：

10.1016/j.nmd.2017.06.421

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

P.381

引用

页码：S211 / S211

页数：1